Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock Rated “Reduce” by Wall Street Analysts

Posted by Stanley Muller on Sep 30th, 2026

Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR – Get Free Report) have earned an average recommendation of “Reduce” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $6.50.

Several brokerages have weighed in on LFCR. Barrington Research downgraded Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research report on Tuesday. Weiss Ratings upgraded shares of Lifecore Biomedical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 9th. William Blair lowered shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a report on Monday. Craig Hallum cut shares of Lifecore Biomedical from a “strong-buy” rating to a “hold” rating in a research report on Monday. Finally, Zacks Research raised shares of Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th.

Check Out Our Latest Research Report on LFCR

Lifecore Biomedical Trading Up 1.1%

LFCR opened at $6.59 on Wednesday. Lifecore Biomedical has a 12 month low of $3.63 and a 12 month high of $8.98. The business’s 50-day moving average price is $4.54 and its 200-day moving average price is $4.77. The company has a market cap of $249.43 million, a P/E ratio of -6.16 and a beta of 1.08.

Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The company had revenue of $34.17 million for the quarter, compared to analysts’ expectations of $34.18 million. Equities research analysts forecast that Lifecore Biomedical will post -1.02 earnings per share for the current fiscal year.

Institutional Trading of Lifecore Biomedical

Several large investors have recently modified their holdings of LFCR. Wittenberg Investment Management Inc. grew its position in shares of Lifecore Biomedical by 26.1% in the 4th quarter. Wittenberg Investment Management Inc. now owns 21,723 shares of the company’s stock worth $178,000 after buying an additional 4,500 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Lifecore Biomedical by 64.4% during the first quarter. Bank of America Corp DE now owns 43,298 shares of the company’s stock valued at $161,000 after acquiring an additional 16,961 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Lifecore Biomedical in the first quarter worth $64,000. Deutsche Bank AG purchased a new stake in Lifecore Biomedical in the second quarter worth $137,000. Finally, Squarepoint Ops LLC boosted its holdings in Lifecore Biomedical by 76.8% in the second quarter. Squarepoint Ops LLC now owns 92,674 shares of the company’s stock valued at $487,000 after acquiring an additional 40,270 shares in the last quarter. 83.36% of the stock is owned by institutional investors.

About Lifecore Biomedical

(Get Free Report)

Lifecore Biomedical, Inc is a contract development and manufacturing organization (CDMO) that provides services to pharmaceutical, biotechnology and medical device companies. The company specializes in complex sterile injectable products and supports customers through product development, process development, manufacturing, aseptic filling, packaging and related regulatory services.

Lifecore’s capabilities include the production of injectable products using fermentation and other specialized manufacturing processes.